[Somatostatin receptor-based imaging and therapy of digestive endocrine tumors].
Identifieur interne : 001651 ( Main/Exploration ); précédent : 001650; suivant : 001652[Somatostatin receptor-based imaging and therapy of digestive endocrine tumors].
Auteurs : RBID : pubmed:21237328Descripteurs français
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- Diagnostic Imaging, Endocrine Gland Neoplasms (radionuclide imaging), Endocrine Gland Neoplasms (radiotherapy), France, Gastrointestinal Neoplasms (radionuclide imaging), Gastrointestinal Neoplasms (radiotherapy), Humans, Indium Radioisotopes (diagnostic use), Neoplasm Staging (methods), Octreotide (diagnostic use), Octreotide (therapeutic use), Pancreatic Neoplasms (radionuclide imaging), Pancreatic Neoplasms (radiotherapy), Positron-Emission Tomography (methods), Radiopharmaceuticals (diagnostic use), Radiopharmaceuticals (therapeutic use), Receptors, Somatostatin (metabolism), Somatostatin (analogs & derivatives).
- MESH :
- chemical , analogs & derivatives : Somatostatin.
- chemical , diagnostic use : Indium Radioisotopes, Octreotide, Radiopharmaceuticals.
- chemical , metabolism : Receptors, Somatostatin.
- chemical , therapeutic use : Octreotide, Radiopharmaceuticals.
- geographic : France.
- methods : Neoplasm Staging, Positron-Emission Tomography.
- radionuclide imaging : Endocrine Gland Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms.
- radiotherapy : Endocrine Gland Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms.
- Diagnostic Imaging, Humans.
Abstract
The management of gastroenteropancreatic endocrine tumors is greatly linked to the localization of primary tumor. Morphological imaging methods are thus necessary. However, the expression of somatostatin receptors in endocrine tumors makes their detection possible thanks to radiolabeled somastotatin analogs. [(111)In-DTPA] octreotide is the main radiolabeled analog for somatostatin receptor scintigraphy. Positron emission tomography uses other tracers and currently allows improvement of the diagnosis and the tumoral staging. It also allows to affect the therapeutic management. A further step is about to be taken as far as the therapy of endocrine tumors is concerned with the peptide receptor radionuclide therapy. Those therapies are now being offered in some European and American centers for progressive metastatic tumors. Their place in the therapeutic strategy has to be defined, especially in comparison to targeted therapy. The sudden and delayed adverse events as well as the current legislation on the use of radioactive therapy-aimed products have limited their development in France so far.
DOI: 10.1016/S0003-4266(10)70002-0
PubMed: 21237328
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Somatostatin receptor-based imaging and therapy of digestive endocrine tumors].</title><author><name sortKey="Illouz, F" uniqKey="Illouz F">F Illouz</name><affiliation wicri:level="3"><nlm:affiliation>Département d'Endocrinologie Diabétologie Nutrition, CHU Angers, 4 rue Larrey 49933 Angers cedex 9, France. frillouz@chu-angers.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département d'Endocrinologie Diabétologie Nutrition, CHU Angers, 4 rue Larrey 49933 Angers cedex 9</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Angers</settlement></placeName></affiliation></author><author><name sortKey="Sadoul, J L" uniqKey="Sadoul J">J-L Sadoul</name></author><author><name sortKey="Rohmer, V" uniqKey="Rohmer V">V Rohmer</name></author></titleStmt><publicationStmt><date when="2010">2010</date><idno type="doi">10.1016/S0003-4266(10)70002-0</idno><idno type="RBID">pubmed:21237328</idno><idno type="pmid">21237328</idno><idno type="wicri:Area/Main/Corpus">001610</idno><idno type="wicri:Area/Main/Curation">001610</idno><idno type="wicri:Area/Main/Exploration">001651</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Diagnostic Imaging</term><term>Endocrine Gland Neoplasms (radionuclide imaging)</term><term>Endocrine Gland Neoplasms (radiotherapy)</term><term>France</term><term>Gastrointestinal Neoplasms (radionuclide imaging)</term><term>Gastrointestinal Neoplasms (radiotherapy)</term><term>Humans</term><term>Indium Radioisotopes (diagnostic use)</term><term>Neoplasm Staging (methods)</term><term>Octreotide (diagnostic use)</term><term>Octreotide (therapeutic use)</term><term>Pancreatic Neoplasms (radionuclide imaging)</term><term>Pancreatic Neoplasms (radiotherapy)</term><term>Positron-Emission Tomography (methods)</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Radiopharmaceuticals (therapeutic use)</term><term>Receptors, Somatostatin (metabolism)</term><term>Somatostatin (analogs & derivatives)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Indium Radioisotopes</term><term>Octreotide</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Octreotide</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Neoplasm Staging</term><term>Positron-Emission Tomography</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Endocrine Gland Neoplasms</term><term>Gastrointestinal Neoplasms</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Endocrine Gland Neoplasms</term><term>Gastrointestinal Neoplasms</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Diagnostic Imaging</term><term>Humans</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The management of gastroenteropancreatic endocrine tumors is greatly linked to the localization of primary tumor. Morphological imaging methods are thus necessary. However, the expression of somatostatin receptors in endocrine tumors makes their detection possible thanks to radiolabeled somastotatin analogs. [(111)In-DTPA] octreotide is the main radiolabeled analog for somatostatin receptor scintigraphy. Positron emission tomography uses other tracers and currently allows improvement of the diagnosis and the tumoral staging. It also allows to affect the therapeutic management. A further step is about to be taken as far as the therapy of endocrine tumors is concerned with the peptide receptor radionuclide therapy. Those therapies are now being offered in some European and American centers for progressive metastatic tumors. Their place in the therapeutic strategy has to be defined, especially in comparison to targeted therapy. The sudden and delayed adverse events as well as the current legislation on the use of radioactive therapy-aimed products have limited their development in France so far.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21237328</PMID><DateCreated><Year>2011</Year><Month>01</Month><Day>17</Day></DateCreated><DateCompleted><Year>2011</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-4266</ISSN><JournalIssue CitedMedium="Internet"><Volume>71 Suppl 1</Volume><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Annales d'endocrinologie</Title><ISOAbbreviation>Ann. Endocrinol. (Paris)</ISOAbbreviation></Journal><ArticleTitle>[Somatostatin receptor-based imaging and therapy of digestive endocrine tumors].</ArticleTitle><Pagination><MedlinePgn>S3-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0003-4266(10)70002-0</ELocationID><Abstract><AbstractText>The management of gastroenteropancreatic endocrine tumors is greatly linked to the localization of primary tumor. Morphological imaging methods are thus necessary. However, the expression of somatostatin receptors in endocrine tumors makes their detection possible thanks to radiolabeled somastotatin analogs. [(111)In-DTPA] octreotide is the main radiolabeled analog for somatostatin receptor scintigraphy. Positron emission tomography uses other tracers and currently allows improvement of the diagnosis and the tumoral staging. It also allows to affect the therapeutic management. A further step is about to be taken as far as the therapy of endocrine tumors is concerned with the peptide receptor radionuclide therapy. Those therapies are now being offered in some European and American centers for progressive metastatic tumors. Their place in the therapeutic strategy has to be defined, especially in comparison to targeted therapy. The sudden and delayed adverse events as well as the current legislation on the use of radioactive therapy-aimed products have limited their development in France so far.</AbstractText><CopyrightInformation>Copyright © 2010 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Illouz</LastName><ForeName>F</ForeName><Initials>F</Initials><Affiliation>Département d'Endocrinologie Diabétologie Nutrition, CHU Angers, 4 rue Larrey 49933 Angers cedex 9, France. frillouz@chu-angers.fr</Affiliation></Author><Author ValidYN="Y"><LastName>Sadoul</LastName><ForeName>J-L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Rohmer</LastName><ForeName>V</ForeName><Initials>V</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType>English Abstract</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Review</PublicationType></PublicationTypeList><VernacularTitle>Imageries et traitements basés sur les récepteurs à la somatostatine dans les tumeurs endocrines digestives.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Ann Endocrinol (Paris)</MedlineTA><NlmUniqueID>0116744</NlmUniqueID><ISSNLinking>0003-4266</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>51110-01-1</RegistryNumber><NameOfSubstance>Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Diagnostic Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Endocrine Gland Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Gastrointestinal Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Staging</DescriptorName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Somatostatin</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Somatostatin</DescriptorName><QualifierName MajorTopicYN="N">analogs & derivatives</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">S0003-4266(10)70002-0</ArticleId><ArticleId IdType="doi">10.1016/S0003-4266(10)70002-0</ArticleId><ArticleId IdType="pubmed">21237328</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001651 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001651 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21237328
|texte= [Somatostatin receptor-based imaging and therapy of digestive endocrine tumors].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21237328" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |